FDA

First Opinion Peter J. Pitts

The FDA’s plan on fluoride supplements is bad science

The Readout LOUD Elaine Chen, Adam Feuerstein, and Matthew Herper

What Vinay Prasad’s ouster means for biotech and the FDA

First Opinion Adam Cifu

STAT Plus: Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Are we sure Vinay Prasad’s ouster is positive for biotech?

A STAT Examination Lizzy Lawrence

STAT Plus: Inside the fall of Vinay Prasad at the FDA

Matt's Take Matthew Herper

STAT Plus: Vinay Prasad was not good for the FDA. But his ouster makes things worse

Pharma Lizzy Lawrence

STAT Plus: FDA names drug regulator Tidmarsh acting head of biologics center after Prasad’s exit

STATus Report Alex Hogan

STAT Plus: STAT breaks down the confusing, heartbreaking Sarepta saga

Politics Lizzy Lawrence, Adam Feuerstein, and Matthew Herper

STAT Plus: Vinay Prasad, a powerful FDA official, departs after controversy over rare disease drug

Politics Lev Facher and Lizzy Lawrence

STAT Plus: Trump administration moves to ban concentrated 7-OH, kratom-related synthetic

First Opinion Frank David

STAT Plus: How the FDA can score quick wins on transparency

Health Lizzy Lawrence

STAT Plus: An unusual FDA panel on antidepressant use during pregnancy elevated skeptics of the drugs

In the Lab Marissa Russo and Jonathan Wosen

STAT Plus: NIH, FDA plan to reduce animal testing draws mixed reactions among scientists

Health Anil Oza

STAT Plus: Safety of fluoride supplements, and freedom of choice, debated at FDA meeting

Health Jason Mast

STAT Plus: For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak

Exclusive Adam Feuerstein and Jason Mast

STAT Plus: Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says

D.C. Diagnosis John Wilkerson

STAT Plus: FDA’s new top drug regulator hails from industry

Biotech Adam Feuerstein

STAT Plus: Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance

Politics Andrew Joseph and Jonathan Wosen

STAT Plus: New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment

First Opinion Grace Colón

STAT Plus: A sloppy report on mifepristone is being used to undermine the FDA — and the biotech industry

Health Tech Newsletter Mario Aguilar

STAT Plus: The FDA-Whoop drama & new details about pharma-telehealth deals

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Inside an FDA drug rejection, and layoffs at Sarepta

Health Associated Press

Juul can continue selling its tobacco and menthol e-cigarettes, FDA says

Lab Dish Paul Knoepfler

STAT Plus: RFK Jr.’s FDA may take cues on stem cells from red-state laws, clinic doctors

Pharmalot Ed Silverman

STAT Plus: A troubled Sun Pharma plant fails yet another FDA inspection

Matt's Take Matthew Herper

STAT Plus: The FDA commissioner is a gifted talker — but the job is about more than that

Biotech Adam Feuerstein

STAT Plus: FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

NIH grant cuts, FDA transparency questions, and biotech M&A

Health Helen Branswell

FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility